53 results
SC TO-T/A
EX-99
Concentra Merger Sub II, Inc.
14 Feb 24
Third party tender offer statement (amended)
10:35am
, at the relevant time, a Person in whose name a CVR is registered in the CVR Register at the applicable time.
“Intended Tax Treatment” has the meaning set … Taxes shall be computed after taking into account any net operating loss carryforwards or other Tax attributes (including Tax credits) of the Company
SC TO-T/A
THRX
Theseus Pharmaceuticals Inc
7 Feb 24
Third party tender offer statement (amended)
5:15pm
, in each case, without interest and subject to any applicable tax withholding, upon the terms and subject to the conditions contained in this Offer
SC TO-T/A
EX-99
THRX
Theseus Pharmaceuticals Inc
30 Jan 24
Third party tender offer statement (amended)
8:23am
), the Offer Price will be paid net of any applicable tax withholding and without interest.
The Offer is being made pursuant to the Agreement and Plan … , without interest and subject to any applicable tax withholding. As of immediately prior to the Effective Time, the vesting for each option to purchase
SC 14D9
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Tender offer solicitation
9:47am
with, Section 262 of the DGCL; and (b) “Cash Amount” means (y) the Base Price Per Share of $3.90 in cash, payable subject to any applicable tax withholding … verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax, accounting and other information supplied
SC TO-T
EX-99
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Third party tender offer statement
8:51am
Price will be paid net of any applicable tax withholding and without interest.
The Offer is being made pursuant to the Agreement and Plan of Merger … under Delaware law, will be converted into the right to receive the Offer Price, without interest and subject to any applicable tax withholding
SC TO-T
EX-99
3y5aobg10m2umsk6 u9
10 Jan 24
Third party tender offer statement
8:51am
SC TO-T
EX-99
m8eadtalcpgga 59bt
10 Jan 24
Third party tender offer statement
8:51am
8-K
EX-2.1
lj6lc02k
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
qdvmvvif
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
EX-10.1
f2vepm dj56m
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
EX-10.3
gjunjtjd85kjqr8it908
4 Dec 23
Departure of Directors or Certain Officers
6:30am
8-K
EX-10.2
tj3ivnt01 nrs0s8
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
PRE 14A
vb5kggn
14 Apr 23
Preliminary proxy
9:00am
S-3
EX-1.2
ncgrw5vwn
3 Nov 22
Shelf registration
9:06am